| Vol. 12.23 – 25 June, 2021 |
| |
|
|
| Investigators demonstrated that mRNA delivery by polymeric nanoparticles could effectively induce expression of phosphatase and tensin homolog deleted on chromosome 10 (PTEN) in Pten-mutated melanoma cells and Pten-null prostate cancer cells. [Science Translational Medicine] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| The authors revealed a role for MUC1-C in regulating PBAF, redox balance, and lineage plasticity of prostate cancer stem cell progression. [Oncogene] |
|
|
|
| Investigators exploited an antibody-based proteomic technology to measure key antigens and activated signaling in extracellular vesicles isolated from sera of prostate cancer patients. [Cell Death & Disease] |
|
|
|
| Scientists investigated whether sequential delivery of fractionated radiotherapy (FRT) followed by vascular-targeted photodynamic therapy (VTP) days later improved flank TRAMP-C1 prostate cancer tumor allograft control compared to monotherapy with FRT or VTP. [British Journal of Cancer] |
|
|
|
| Researchers analyzed the efficacy and mechanistic interactions of PARP inhibition and CDK4/6 inhibition (CDK4/6i) combination therapy in CRPC and neuroendocrine prostate cancer models. [Molecular Cancer Therapeutics] |
|
|
|
| The authors presented a single-circulating tumor cell (CTC) sensitive digital droplet PCR assay for the quantitation of the two most common androgen receptor variants (AR-Vs), AR-V7, and AR-v567es, using antigen agnostic CTC enrichment. [Communications Biology] |
|
|
|
| Inhibition of MCM2-7 by treatment with ciprofloxacin inhibited neuroendocrine prostate cancer (NEPC) cell proliferation and migration in vitro, significantly delayed NEPC tumor xenograft growth, and partially reversed the neuroendocrine phenotype in vivo. [Scientific Reports] |
|
|
|
| Several studies have identified that circular RNAs (circRNAs) have a crucial impact on the biological processes in prostate cancer. Researchers studied the molecular mechanism of circRNAs in tumor progression and metastasis. [Clinical and Translational Oncology] |
|
|
|
| To model the problem of radiation resistance in prostate cancer, cell lines mimicking a clinical course of conventionally fractionated or hypofractionated radiotherapy were generated. [Proteomics Clinical Applications] |
|
|
|
|
| Scientists discuss recent advances in understanding the cell types of origin, putative cancer stem cells, and tumor plasticity in prostate cancer, focusing on insights from studies of genetically engineered mouse models. [Seminars in Cancer Biology] |
|
|
|
| Studies applying post-exercise blood serum directly to various types of cancer cell lines provide insight that exercise might have a role in inhibiting cancer growth via altered soluble and cell-free blood contents. [Nature Reviews Urology] |
|
|
|
| | AstraZeneca and Merck announced that LYNPARZA ® has been granted conditional approval in China as monotherapy for the treatment of adult patients with germline or somatic BRCA-mutated metastatic CRPC who have progressed following prior treatment that included a new hormonal agent. [Merck] |
|
|
|
| Pfizer Inc. announced that the first participant has been dosed in TALAPRO-3, a global, randomized, double-blind, placebo-controlled Phase III clinical trial. The study will evaluate the efficacy and safety of talazoparib in combination with enzalutamide compared with placebo plus enzalutamide in men with DNA damage response-deficient mCSPC. [Pfizer Inc.] |
|
|
|
|
| October 7 – 11, 2021 Virtual |
|
|
|
|
|
| Mayo Clinic Health System – Rochester, Minnesota, United States |
|
|
|
| Henry M Jackson Foundation for the Advancement of Military Medicine – Bethesda, Maryland, United States |
|
|
|
| Institute of Oncology Research – Bellinzona, Switzerland |
|
|
|
| University of Texas MD Anderson Cancer Center – Houston, Texas, United States |
|
|
|
| Emory University – Atlanta, Georgia, United States |
|
|
|
|